ZIVO Zivo Bioscience, Inc. Insider Trading

10% owner STROME MARK E buys 100.0K ZIVO shares at $2.00; stock down -93.7% from 52-week high, down -85.4% in 30 days.

STROME MARK E, a 10% owner, purchased 100,000 shares at $2.00 on 2026-04-17, increasing holdings by 21.1% to 572,942 shares. The timing is concerning: the stock trades at $1.20, down -93.7% from its 52-week high of $19.01 and down -85.4% over the past 30 days. His track record at this same ticker shows poor outcomes—three prior buys at ZIVO resulted in average 90-day returns of -15.1% (2024-12-26 buy down -15.3%, 2025-10-13 buy down -24.6%), with 0 of 2 prior buys well-timed at the 90-day mark. This latest purchase into a steep and accelerating decline, following a pattern of unsuccessful accumulation at ZIVO, suggests the insider's recent capital deployment has not been rewarded. The company remains unprofitable with net income of $-1.0M, adding fundamental risk to the price deterioration.

Director Laith Yaldoo buys 1,543 shares of ZIVO at $9.72; stock down -56.0% from 52-week high, unprofitable company with 468.6% annual revenue growth.

Director Laith Yaldoo purchased 1,543 shares at $9.72 on 2026-02-27, raising his holdings to 583.6K shares. The purchase occurs in a weak near-term context: the stock has declined 11.9% over the past 30 days and trades 56.0% below its 52-week high of $21.00. Examining his same-ticker history at ZIVO, Yaldoo has made 5 prior purchases, with a 90-day win rate of only 1 of 3 measurable outcomes—a low success rate. The company remains fundamentally challenged, posting a net loss of $1.0M against quarterly revenue of $65.6K, though annual revenue growth of 468.6% indicates potential scaling. The small transaction size (0.3% of post-transaction holdings) and recurring buy pattern despite poor historical returns at this ticker suggest routine accumulation rather than a conviction-driven entry point during market stress.

10% Owner Strome buys 20,000 ZIVO shares at $9.77; stock at -53.5% from 52-week high, prior buys at this ticker showed 90d losses.

Mark E. Strome, a 10% shareholder, purchased 20,000 shares at $9.77, increasing his holdings from 452.9K to 472.9K shares. The transaction occurred at a significant discount to the 52-week high of $21.49, but Strome's own track record at this ticker shows two prior buys (2025-10-13 and 2024-12-26) that each declined over 90 days (-3.6% and -24.6% respectively), with a 0% success rate at the 90-day mark. The company remains unprofitable with a net loss of $1.0M in the most recent period, offsetting strong revenue growth of 468.6% year-over-year. While the recent 30-day price appreciation of +11.1% may have prompted the purchase, the lack of prior successful timing by this insider at ZIVO and the company's continued losses present a cautious context for this accumulation.

Director Yaldoo Laith L buys 2,434 shares of ZIVO at $10.27, now -54.0% from 52-week high; holds 582.1K shares post-trade.

Director Yaldoo purchased 2,434 shares at $10.27 on 2026-02-10, adding modestly to an already substantial 582.1K-share position. The timing relative to the stock's 52-week range is notable: the purchase occurred at $10.27, which is now -54.0% from the 52-week high of $21.49, suggesting the director bought into a substantially depressed price. However, his prior trades at ZIVO show a troubling pattern—of 3 prior measurable 90-day outcomes at this ticker, 0 were well-timed (all showed negative 90-day returns: -9.3%, -22.8%, and -43.4%), indicating a consistent pattern of buying before further declines. The company's fundamentals remain challenging: revenue is only $65,625.00 for the latest quarter against a net loss of $-1,033,056.00, with market cap of $38,419,318.60. While annual revenue growth reached +468.6%, unprofitability persists, creating uncertainty about the business's sustainability and the rationale behind continued accumulation.

Director Cornell buys 11,709 shares of ZIVO at $8.54; stock at $9.00, down 58.1% from $21.49 peak; prior 2 buys perfectly timed (90d: +85.8%, +558.3%)

Director Alison A Cornell purchased 11,709 shares at $8.54, raising her stake by 4.4% to 279,481 shares post-transaction. The stock is currently trading at $9.00, down 58.1% from its 52-week high of $21.49 and down 35.7% over the past 90 days, suggesting a sharp drawdown. Cornell's prior buying activity at ZIVO demonstrates strong timing: her 2024-08-22 buy returned +85.8% over 30 days and +151.3% over 90 days, while her 2024-01-02 buy returned +558.3% over 30 days and +524.9% over 90 days—both well-timed entries. This current purchase occurs alongside 3 other insider buys within the past 14 days, forming a cluster pattern. The company is unprofitable (full-year net income was negative) with only $65.6K in latest quarterly revenue, though annual revenue growth reaches +468.6%. Cornell's consistent track record of well-timed entries at this ticker is notable, but the stock's recent steep decline and the company's weak fundamentals warrant close observation of whether this accumulation phase signals a genuine inflection point.

ZIVO CEO John Bernard Payne buys 11,709 shares at $8.54 (2026-01-26); holdings +148.0%; cluster activity detected.

CEO John Bernard Payne purchased 11,709 shares at $8.54 on 2026-01-26, increasing his holdings by 148.0% from 7,909 to 19,618 shares, with a total transaction value of $99,994.86. This buy coincides with 3 other insiders buying within the past 14 days, indicating a cluster buy pattern. Zivo Bioscience is currently unprofitable (net income of $-1,033,056.00 for the latest full fiscal year) but shows strong annual revenue growth of +468.6%, though quarterly revenue remains modest at $65,625.00. The stock has declined 58.1% from its 52-week high of $21.49 and is trading at $9.00, down 35.7% over 90 days, yet the insider's prior purchase at this ticker in 2024 delivered positive 90-day returns, consistent with his 100% win rate across his cross-ticker track record.

Director Maggiore buys 1,766 shares of ZIVO at $8.49; 4 of 5 prior same-ticker buys achieved positive 90d returns; cluster buy underway.

Christopher D. Maggiore, a director, purchased 1,766 shares at $8.49, bringing holdings to 519,292 shares. This is the sixth buy signal in his cross-ticker track record with a 90-day win rate of 83.33%, though his specific same-ticker history shows mixed results: 4 of 5 prior ZIVO purchases were well-timed at the 90-day mark, but the most recent buy on 2025-10-08 underperformed with -23.0% over 90 days. The timing context is notable given the stock is -54.6% from its 52-week high and +39.3% over the last 30 days, suggesting he is buying into recent momentum. Additionally, 3 other insiders have purchased within the past 14 days, forming a cluster buy pattern that may signal coordinated conviction around current valuation levels.

Director Yaldoo buys 1,766 shares at $8.49 (down 54.6% from 52-week high); prior ZIVO buys show 0 of 4 were well-timed at 90 days, 3-insider cluster.

Yaldoo Laith L, a director, purchased 1,766 shares of ZIVO at $8.49 on 2026-01-14 while the stock trades 54.6% below its 52-week high of $21.49. His SAME-TICKER HISTORY shows a concerning pattern: of his 4 prior measurable ZIVO buy trades, none achieved positive 90-day returns, with outcomes ranging from -9.3% to -43.4%. The current purchase occurs within a cluster of 3 other insider buys in the past 14 days, but his track record at this specific ticker does not support a view that he times his purchases effectively—4 of 4 prior attempts lost value over the 90-day window. The company reported revenue of $65.6K and a net loss of $1.0M in the latest quarter, with full-year profitability also negative, raising questions about the operational foundation for the stock's recovery.

Director Yaldoo purchases 2,777 shares of ZIVO at $9.00; stock down -39.1% in 90 days, 0 of 3 prior same-ticker buys well-timed.

Director Laith L Yaldoo purchased 2,777 shares at $9.00 on 2025-11-28, raising holdings to 577,872 shares. The stock has declined significantly since the transaction, with current price at $10.35 representing a -26.1% decline over the past 30 days and -39.1% over 90 days from a 52-week high of $22.10. Examining same-ticker execution history reveals a consistent pattern of poor timing: the director's 5 prior trades at ZIVO show 0 of 3 measurable buys achieved positive 90-day returns, with prior purchases on this stock returning -9.3%, -31.5%, and -31.5% over 90 days. The company's fundamentals show recent quarterly revenue of $65,625.00 against a net loss of $-1,033,056.00, with market capitalization of $40,246,958.25, indicating structural profitability challenges. This purchase adds to a pattern of accumulation into a declining asset without evident positive outcomes from prior timing decisions at this ticker.

10% owner Mark Strome bought 20,259 shares of ZIVO at $12.34; cluster buy by 2 other insiders in 14 days

Mark Strome, a 10% shareholder, purchased 20,259 shares at $12.34 on 2025-10-13 for $249,996.06, increasing his holdings to 452,942 shares (+4.7%). This buy occurred as part of a cluster pattern, with 2 other insiders also purchasing within the past 14 days. However, context dampens the signal: Strome's prior buy at ZIVO (2024-12-26) resulted in -15.3% return over 90 days, and his cross-ticker track record shows 0 of 1 prior buys well-timed at the 90-day mark. The company's fundamentals are weak—it posted $-1,640,232.00 net income on $53,400.00 quarterly revenue and remains unprofitable, though annual revenue growth reached +468.6%. The stock is down -38.9% from its 52-week high, trading at $13.50 versus the $12.34 transaction price. The multi-insider buying gesture and recent revenue growth stand against a pattern of insider losses and persistent unprofitability.